Currently, ASCO recommends pembrolizumab as a first-line drug in combination with chemotherapy for refractory locally advanced or metastatic esophageal and gastroesophageal junction adenocarcinomas and squamous cell carcinomas, regardless of PD-L1 expression. The gene discussed is CD274; the disease is squamous cell carcinoma.